Chest X-ray study - Accellacare

Project Overview

This Phase 3 study was designed to evaluate the efficacy, safety and tolerability of TAK-279 in adults with moderate-to-severe plaque psoriasis.

Diagnostic imaging formed an important part of the participant screening process, supporting eligibility confirmation and baseline clinical assessment prior to randomisation.

LivingCare was engaged to deliver this imaging activity within the defined screening window, ensuring timely progression into the treatment phase of the study.

Our Role

LivingCare supported the study by delivering diagnostic imaging during the screening phase, working within a regulated clinical environment to meet study timelines and quality requirements.

Imaging appointments were coordinated and delivered within the 7 to 35-day screening period, enabling study investigators to complete eligibility assessments without delay.

All scans were carried out in line with required technical standards and governance frameworks, with outputs provided to support baseline clinical evaluation. Treatment allocation, investigational product management and wider clinical assessments remained under sponsor and investigator oversight.

Outcomes

LivingCare successfully delivered time-sensitive imaging within the defined screening window, supporting participant progression into randomisation and maintaining study momentum.

Imaging was completed to the required quality standards and within expected timelines, contributing to efficient screening activity across UK sites.

The reliable delivery of imaging support helped minimise delays during enrolment and demonstrated LivingCare’s capability to support complex Phase 3 studies with short, critical delivery windows.

• Experience supporting imaging for late-phase clinical trials
• Ability to deliver scanning within tight screening timeframes
• Strong clinical governance and quality assurance
• Clear coordination with research teams